Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
B-cell Lymphoma clinical trials
Every US clinical trial registered for B-cell Lymphoma — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
11 US clinical trials · 6 currently recruiting
The research picture
B-cell Lymphoma has 11 registered US clinical trials, 6 of them open to new participants right now — about 55% of the total.
- 6
- recruiting participants now
- 55%
- of trials open to enrollment
- 0
- in Phase 3–4 (later-stage)
- 1
- top sponsor: Pharmacyclics
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics
NCT05365659
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
NCT05643742
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
NCT06634589
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Brown University
NCT04792502
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech
NCT05653271
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Rita Assi
NCT06484920
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Eli Lilly and Company
NCT05024045
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
Medical College of Wisconsin
NCT05270057
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Pharmacyclics
NCT01980628
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TG Therapeutics
NCT01647971
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT03734601
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the B-cell Lymphoma Trial Landscape
ClinicalTrials.gov lists 11 US studies indexed under B-cell Lymphoma, and 6 of those are currently open to recruitment — roughly 55% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for B-cell Lymphoma shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 11 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for B-cell Lymphoma is led by Pharmacyclics with 1 indexed trial, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 11 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for B-cell Lymphoma?
PlainTrial tracks 11 US clinical trials for B-cell Lymphoma, of which 6 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for B-cell Lymphoma?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.